Last $0.20 USD
Change Today +0.01 / 5.26%
Volume 11.8K
INNV On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).

innovus pharmaceuticals inc (INNV) Snapshot

Open
$0.20
Previous Close
$0.19
Day High
$0.24
Day Low
$0.20
52 Week High
09/23/13 - $1.16
52 Week Low
07/8/14 - $0.11
Market Cap
4.8M
Average Volume 10 Days
5.3K
EPS TTM
$-0.26
Shares Outstanding
23.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INNOVUS PHARMACEUTICALS INC (INNV)

Related News

No related news articles were found.

innovus pharmaceuticals inc (INNV) Related Businessweek News

No Related Businessweek News Found

innovus pharmaceuticals inc (INNV) Details

Innovus Pharmaceuticals, Inc., a pharmaceutical company, is engaged in the commercialization, licensing, and development of non-prescription pharmaceutical and consumer health products in the United States and internationally. Its male and female sexual health and vitality products include EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; CIRCUMserum, a non-medicated cream to alleviate reduced penile sensitivity; Zestra, a non-medicated patented natural product to increase desire and arousal, and reduce pain from sexual intercourse in women; and Zestra Glide, a clinically tested water-based longer lasting lubricant. The company also provides pain management products comprising Apeaz, an OTC monograph-compliant topical cream for the relief of arthritis pain; and Xyralid, an OTC monograph compliant lidocaine-based spray in development for the relief of hemorrhoids. It markets its products directly or through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through on-line channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. is based in San Diego, California.

2 Employees
Last Reported Date: 03/28/14

innovus pharmaceuticals inc (INNV) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

innovus pharmaceuticals inc (INNV) Key Developments

Innovus Pharmaceuticals, Inc. Presents at FSXinterlinked Investment Conference, Jul-31-2014 01:57 PM

Innovus Pharmaceuticals, Inc. Presents at FSXinterlinked Investment Conference, Jul-31-2014 01:57 PM. Venue: Four Seasons Westlake Village, California, United States. Speakers: Bassam B. Damaj, Chief Executive Officer, President and Director.

Innovus Pharmaceuticals, Inc. Announces the Beginning of Patient Enrollment in its Post-Marketing EjectDelay Clinical Study in the Middle East

Innovus Pharmaceuticals, Inc. announced that patient enrollment has begun in its EjectDelay post-marketing clinical study in Lebanon. The study is being run at the Lebanese-Canadian Hospital in Beirut, Lebanon. EjectDelay's active ingredient is a proprietary fast absorbing and vanishing gel formulation with the active drug benzocaine at 7.5% designed to reduce transfer to the partner. The study is a placebo-controlled, parallel, double-blind study for 12 weeks of treatment. The study will enroll a total of 50 patients. The primary endpoint of the study is the evaluation of the Intra-Vaginal Ejaculatory Time achieved by the product in patients with premature ejaculation in this Middle Eastern population and the effect of the product on the female partner. The Middle East and North Africa market is a large market for these two indications and the two studies, once successfully completed, will be the first controlled data to be reported in such a patient population. EjectDelay is an over-the-counter U.S. Food and Drug Administration-compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation. The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes.

Innovus Pharma Announces Availability of EjectDelay for Premature Ejaculation in the United States

Innovus Pharmaceuticals, Inc. announced the availability of its over the counter benzocaine-based topical premature ejaculation treatment EjectDelay in the United States. The EjectDelay product license has been approved in Canada and the Company expects to launch the product in the Canadian market in 2014. EjectDelay is an over-the-counter U.S. Food and Drug Administration and Health Canada-compliant proprietary topical treatment containing the drug benzocaine and indicated for the treatment of delayed premature ejaculation. The drug typically works within minutes of application to the glans of the penis. In clinical trials, the application of benzocaine has been shown to delay premature ejaculation by several minutes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INNV:US $0.20 USD +0.01

INNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for INNV.
View Industry Companies
 

Industry Analysis

INNV

Industry Average

Valuation INNV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.8x
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INNOVUS PHARMACEUTICALS INC, please visit www.innovuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.